NEW YORK (GenomeWeb) – 23andMe announced today that it has partnered with Celmatix, a personalized medicine company focused on fertility and women's health, to develop and validate biomarkers to diagnose and treat infertility.
Celmatix will contribute data from its discovery and annotation of more than 5,200 genetic biomarkers related to fertility, and 23andMe will add its genetic database and research community knowledge to the collaboration.
The effort will accelerate the launch of Celmatix's genetic infertility tests, and will enable the development of early screening tests to help doctors identify women at risk of premature ovarian function decline, 23andMe said.
"The scale of the genetic data that 23andMe has amassed is unprecedented for the field of reproductive medicine," said Celmatix Founder and CEO Piraye Yurttas Beim in a statement. "Celmatix has worked for six years in partnership with the top fertility centers in the world to vet, validate, and discover novel genetic biomarkers that will dramatically impact the diagnosis and treatment of infertility. This collaboration allows us to further accelerate this work."
Celmatix has also amassed a large database on infertility treatments through its data platform and network of clinics, added Emily Drabant, 23andMe's vice president of business development. "Combining that platform with 23andMe's massive genetic database will create a uniquely powerful engine to fuel discoveries on the genetics of infertility," she said.